Research and Markets: Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3vvmps/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cariprazine for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

  • Etiology and Pathophysiology
  • Classification
  • Symptoms and Subtypes of Major Depressive Disorder
  • Prognosis
  • Quality of Life

4 Disease Management

  • Diagnosis
  • Treatment Guidelines and Leading Prescribed Drugs
  • Clinical Practice

5 Competitive Assessment

6 Unmet Needs and Opportunities

  • More Effective Pharmacotherapies
  • More Favorable Side Effect Profiles
  • Rapid Onset of Antidepressant Effects
  • Personalized Treatment Approach

7 Pipeline Assessment

8 Cariprazine (RGH-188)

9 Appendix

For more information visit http://www.researchandmarkets.com/research/3vvmps/cariprazine

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System